XBKK
RJH
Market cap106mUSD
Nov 12, Last price
12.20THB
Name
Rajthanee Hospital PCL
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rajthanee Hospital Public Company Limited, along with its affiliated businesses, delivers a comprehensive array of medical services across Thailand. The company provides various healthcare offerings, including general treatment, wellness improvement, rehabilitation, and disease prevention, catering to both common and severe illnesses through its team of general and specialized medical professionals. Its extensive departmental coverage includes internal medicine, surgical procedures and orthopedics, pediatric care, obstetrics and gynecology, ear, nose, and throat (ENT), eye care, anesthesia, diagnostic imaging, and dentistry. Additionally, Rajthanee Hospital manages specialized units such as emergency and brain neurosurgery, cardiology, surgery, orthopedics, preventive health check-ups, radiology, general diagnostics, ophthalmology, hemodialysis, sleep disorder testing, and dental centers. Established in 1990, the company's principal office is located in Phra Nakhon Si Ayutthaya, Thailand.
Key people
Kanokrin Boonvisut
Deputy Hospital Director · since 2020
Manassa Lerddamrongluck
Assistant Hospital Director - Accounting and Finance · since 2017
Chatcharin Pinsuwan
Hospital Director · since 2019
Benja Ruangsri
Accounting Manager · since 2017
Tanunya Nuthong
Company Secretary · since 2023
Phitrampha Prasithirun
Director · since 2024
Phitraphee Prasithirun
Director · since 2015
Surin Prasithirun
Chairman of the Executive Board, Managing Director, Director · since 2019
Charoonsak Sripochsomboon
Director · since 2006
Porntip Wudhikulprapan
Director · since 2017
Wachira Wudhikulprapan
Director · since 2019
Sudtida Jirapatsakul
Independent Chairman of the Board · since 2023
Sutti Kittisuppaporn
Independent Director · since 2023
Adisorn Thavornthanasarn
Independent Director · since 2023
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||